For the Inventor, By the Inventor

Enter assignee name

Wuppertal, Germany

Aicuris Anti-Infective Cures Gmbh

USPTO Granted Patents = 9

CIPO Patents = 1

EPO Patents = 6

Forward Citations = 26

Loading Chart...

Loading Chart...

44 inventors (with patents filed for the assignee):

Wilfried Schwab (7 out of 46 patents)

Alexander Birkmann (5 out of 11 patents)

Kerstin Paulus (3 out of 8 patents)

4. Kurt Vogtli (3 out of 5 patents)

5. Dieter Haag (3 out of 5 patents)

6. Stephan Maas (3 out of 5 patents)

7. Kristian Ruepp (3 out of 5 patents)

8. Yogeshwar Bachhav (2 out of 5 patents)

9. Kurt Voegtli (2 out of 3 patents)

10. Christian Sinzger (1 out of 2 patents)

11. Cora Stegmann (1 out of 1 patent)

12. Kerstin Laib Sampaio (1 out of 1 patent)

13. Barbara Adler (1 out of 1 patent)

14. Dieter Lang (1 out of 67 patents)

15. Ulrich Betz (1 out of 11 patents)

9 patents: Sort by Forward Citations

1. 12152022 - N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof (2024-11-26),

2. 11390661 - HCMV entry inhibitors (2022-07-19),

3. 11021474 - N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof (2021-06-01),

4. 10442773 - Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration (2019-10-15),

5. 10137117 - Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations (2018-11-27),

6. RE46791 - Substituted dihydroquinazolines (2018-04-16),

7. 9890128 - Process for making substituted quinazoline compounds (2018-02-13),

8. 9889124 - Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations (2018-02-13),

9. 9592225 - Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations (2017-03-14),

Aicuris Anti-infective Cures GmbH is a biopharmaceutical company focusing on the discovery and development of novel antiviral and antibacterial agents. With a strong focus on anti-infective cures, the company is committed to addressing unmet medical needs and developing innovative therapies to combat infectious diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

9 Patents

#46 in Wuppertal

#4,036 in Germany

Wuppertal, Germany

Aicuris Anti-Infective Cures Gmbh

Forward Citations = 26

44 inventors:

Wilfried Schwab (7 out of 46 patents)

Alexander Birkmann (5 out of 11 patents)

Kerstin Paulus (3 out of 8 patents)

4. Kurt Vogtli (3 out of 5 patents)

5. Dieter Haag (3 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…